



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose. **Indicates that this individual's presentation(s) ***will include*** discussion of off-label or unapproved usage.

Mohammed Abou El Fadl, M.D.
Sanya Arscott, R.N.
Star Belnap, Ph.D.
Iahn Cajigas, M.D., Ph.D.
Nina Cruz, MSN
Felipe De Los Rios La Rosa, M.D.
Karel Fuentes, M.D.
Aimee Green, APRN
Jessica Greenwood, Pharm.D.**
Mark N. Hadley, M.D.
Kendra Kent, R.N., M.S.

Laiqua Khalid, M.D.
Dawn Kleindorfer, M.D.
Jonathan Kline, Pharm.D.
Nerissa Ko, M.D.
Jason Liounakos, M.D.
Javier Lopez, M.D.
Moises Lustgarten, M.D.
Jamelah Morton, APRN
Luis Orengo, M.D.
Cristina Parsons, P.T.
Alex Perez, BSN, R.N.
Jessilyn Pozo, R.N.

John Ragheb, M.D.**
Tarak Rambhatla, M.D.
Robert Rothrock, M.D.
Vitaly Siomin, M.D.
Justin Sporrer, M.D.
Ronald Tolchin, D.O.
Alexandra Turcios, MSN
Raul Vasquez-Castellanos, M.D.
Jobyna Whiting, M.D.
Robert Wicks, M.D.**
Thomas Wolfel, Pharm.D.**

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies* to disclose.

Aviva Abosch, M.D.,** receives research support from and is a consultant for Medtronic.

Kevin Abrams, M.D., is a consultant for Keystone Heart and Viz.AI, and is a stockholder in Cleerly and Viz.AI.

Guilherme Dabus, M.D., is a consultant for Penumbra, Microvention, Cerenovus, Stryker, Medtronic, Route92 and InNeuroCo, and a member of the speakers' bureau for Penumbra, Microvention, Stryker, Medtronic and Route92; also, he has an executive role with NeuroTactical Strategies and is a stockholder in Three Rivers Medical, NeuroFine, Deinde, InNeuroCo, Cleerly, Synchron, RIST, Amgen, Regeneron, eLum, Hyperion and GHIF.

Ian Del Conde Pozzi, M.D., is a member of the speakers' bureau for Abbott, Boston Scientific, Janssen and Pfizer Pharmaceuticals.

Kelly Foote, M.D.,** receives research support and fellowship support from and is a consultant to Boston Scientific and Medtronic; also, he receives research support from Functional Neuromodulation.

Michael Gomez, M.D., is a consultant for Depuy.

Italo Linfante, M.D.,** is a consultant for Medtronic, Cerenovus and Stryker, and a member of the speakers' bureau for Medtronic; also, he is a stockholder in InNeuroCo, Three Rivers Medical, Deinde Medical and Prolong Pharmaceuticals.

Michael McDermott, M.D., is a consultant for Deinde Medical and Stryker.

Srikanth Nagalla, M.D., is a consultant for Alexion Pharmaceuticals, Sanofi, Kedrion and Alnylam Pharmaceuticals, and a member of the speakers' bureaus for Sanofi, Sobi and Rigil; also, he is a stockholder in Gilead, Nine Meters Biopharma, Moderna, Novavax, Phio Pharmaceuticals and Therapeutic Solutions International. **Note:** The consulting relationships with Kedrion and Alnylam ended within the past 24 months.

Alberto Pinzon-Ardila, M.D, Ph.D., is a member of the speakers' bureau for SK Pharmaceuticals, Sunovion Pharmaceuticals and UCB.

Jose Javier Provencio, M.D.,** is an adviser to Cryothermics and is a consultant to and receives research support from Minnetronix.

Diego Torres-Russotto, M.D.,** is a consultant for Acorda, AbbVie-Allergan IPSEN, Kyowa Kirin, Revance, Sunovion and Teva.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*